Cargando…
Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer
Anthracycline drugs are considered to be pivotal drugs in numerous chemotherapy regimens for breast cancer. However, the cardiotoxicity associated with the treatment is an important issue to be addressed. With the emergence of increasingly diverse antitumor drugs, anthracycline-free therapies are ab...
Autores principales: | Guan, Jingyuan, Zhang, Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751370/ https://www.ncbi.nlm.nih.gov/pubmed/33376533 http://dx.doi.org/10.3892/ol.2020.12361 |
Ejemplares similares
-
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study
por: Lu, Hang, et al.
Publicado: (2023) -
Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016) -
Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer
por: Kok, Cindy Y., et al.
Publicado: (2021) -
Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)